New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
New Drug Update 2010-2011 Faculty Disclaimer - CME Conferences
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2 nd Annual Essentials in Primary Care<br />
Fall Conference<br />
Friday, November 11, <strong>2011</strong><br />
Dabigatran- Pradaxa<br />
Table 1: Event rates by INR time in range vs dabigatran 110 BID and 150 mg BID<br />
Event %/yr<br />
Stroke* +<br />
SEE<br />
Warf<br />
n=6022<br />
Warf Q 4<br />
TTR < 53%<br />
Warf Q 1-2<br />
TTR > 67%<br />
Dabig 110<br />
n=6015<br />
Dabig 150<br />
n=6076<br />
1.69 2.2 1.3 1.53 1.11**<br />
NNT 173<br />
Maj Bld 3.36 4.6 2.7 2.71** 3.11<br />
MI 0.53 Na Na 0.72 0.74**<br />
NNH 476<br />
Comp. 7.64 11.9 5.3 7.09 6.91<br />
*"Stroke" includes hemorrhagic stroke, **stat. sig. vs warfarin in original report.<br />
Comp = Stroke, systemic embolism, MI, PE, death, major bleeding. Warf 4th quartile = ITTR < 53.4%,<br />
1st & 2nd quartile = ITTR > 67.1%.<br />
N Engl J Med 2009; 361:1139-1151<br />
Dabigatran- Pradaxa<br />
Risk of extracranial and intracranial bleeding (% per year) by age<br />
End point<br />
Warfarin<br />
(%)<br />
Dabigatran 110<br />
mg (%)<br />
Dabigatran 150<br />
mg (%)<br />
P<br />
Extracranial bleeding<br />
Age 75 3.44 4.10 4.68 0.001<br />
Intracranial bleeding<br />
Age 75 1.00 0.37 0.41 0.28<br />
Circulation <strong>2011</strong>;123:2363-2372<br />
Wayne Weart<br />
<strong>New</strong> <strong>Drug</strong> <strong>Update</strong> Part I
Change language